SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Tekla Capital Management LLC

CIK 0001300336 · 100 FEDERAL STREET, 19TH FLOOR, BOSTON, MA, 02110 · 617 772-8500

Reported Value
$2.3B
Q3 2019
Positions
192
Filings on Record
19
2019–present window
Filed
Nov 13, 2019
original filing

Summary

Tekla Capital Management LLC reported $2.3B in U.S.-listed holdings across 192 positions for Q3 2019.

Its largest position, CELG, represents 6.4% of the portfolio.

Compared with Q2 2019, the fund opened 14 new positions and exited 19.

Portfolio Metrics

Turnover
+6.7%
vs prior filed quarter
Top-10 Concentration
+41.8%
share of reported value
Largest Position
+6.4%
Celgene
New / Exited
14 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.3BQ4 ’18Q1 ’19: $2.5BQ2 ’19: $2.5BQ3 ’19: $2.3BQ3 ’19Q4 ’19: $2.6BQ1 ’20: $2.2BQ2 ’20: $2.6BQ2 ’20Q3 ’20: $2.7BQ4 ’20: $2.8BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $3.1BQ3 ’21: $3.1BQ4 ’21: $3.1BQ4 ’21Q1 ’22: $2.8BQ2 ’22: $2.5BQ3 ’22: $2.4BQ3 ’22Q4 ’22: $2.6BQ1 ’23: $2.6BQ2 ’23: $2.6BQ2 ’23filingsflow.com

Portfolio Composition

By security type
Common Stock: 83.9%Other: 8.5%ADR: 4.1%REIT: 3.1%ETP: 0.4%Other: 0.1%
  • Common Stock · 83.9% · $1.9B
  • Other · 8.5% · $194M
  • ADR · 4.1% · $93M
  • REIT · 3.1% · $72M
  • ETP · 0.4% · $9M
  • Other · 0.1% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IM8NInsmed Inc.NEW+164.8K164.8K+$3M$3M
PACBPacific Biosciences of California, Inc.NEW+495.5K495.5K+$3M$3M
RCKTRocket Pharmaceuticals, Inc.NEW+207.6K207.6K+$2M$2M
APLSUSDApellis Pharmaceuticals, Inc.NEW+98.8K98.8K+$2M$2M
Quotient Ltd.NEW+260.0K260.0K+$2M$2M
iShares Nasdaq Biotechnology ETFNEW+18.9K18.9K+$2M$2M
PKNPerkinElmer, Inc.NEW+19.0K19.0K+$2M$2M
Biohaven Pharmaceutical Holding Company Ltd.NEW+29.1K29.1K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CELGCelgene Corp.history →Common6.38%$146M1.47M
2AMGNAmgen Inc.history →Common5.34%$122M632.3K
3GILDGilead Sciences, Inc.history →Common5.07%$116M1.83M
4JNJJohnson & Johnsonhistory →Common4.62%$106M818.2K
5MRKMerck & Co., Inc.history →Common4.45%$102M1.21M
6VRTXVertex Pharmaceuticals Inc.history →Common3.60%$83M487.2K
7PFEPfizer Inc.history →Common3.31%$76M2.11M
8ILMNIllumina, Inc.history →Common3.20%$73M241.1K
9UNHUnitedhealth Group Inc.history →Common3.20%$73M337.3K
10BIIBBiogen Inc.history →Common2.62%$60M257.9K
11ALXNAlexion Pharmaceuticals, Inc.history →Common1.94%$44M453.9K
12REGNRegeneron Pharmaceuticals, Inc.history →Common1.93%$44M159.7K
13Medtronic plcShares1.89%$43M399.4K
14BMYBristol-Myers Squibb Co.history →Common1.63%$37M738.0K
15CVSCVS Health Corp.history →Common1.49%$34M540.3K
16ZTSZoetis Inc.history →Class A1.35%$31M249.0K
17ABBVAbbVie Inc.history →Common1.32%$30M400.0K
18ISRGIntuitive Surgical, Inc.history →Common1.31%$30M55.5K
19INCYIncyte Corp.history →Common1.28%$29M393.7K
20ELVAnthem, Inc.history →Common1.27%$29M121.1K
21ABTAbbott Laboratorieshistory →Common1.18%$27M322.5K
22TMOThermo Fisher Scientific Inc.history →Common1.13%$26M89.3K
23SYKStryker Corp.history →Common1.12%$26M118.5K
24SGENUSDSeattle Genetics, Inc.history →Common1.08%$25M289.9K
25Allergan plcShares1.07%$24M145.3K
26BSXBoston Scientific Corp.history →Common1.00%$23M565.0K
27DHRDanaher Corp.history →Common0.96%$22M152.4K
28NVSNNovartis AGhistory →Sponsored ADR0.95%$22M249.4K
29HUMHumana Inc.history →Common0.94%$22M84.2K
30Mylan N.V.Shares0.90%$21M1.04M
31CICigna Corp.history →Common0.83%$19M125.0K
32NBIXNeurocrine Biosciences, Inc.history →Common0.81%$19M206.8K
33LLYEli Lilly and Co.history →Common0.77%$18M157.0K
34BMRNBioMarin Pharmaceutical Inc.history →Common0.72%$17M245.8K
35PRAHPRA Health Sciences, Inc.history →Common0.66%$15M153.0K
36BDXBecton, Dickinson and Co.history →Common0.64%$15M58.4K
37MCKMcKesson Corp.history →Common0.64%$15M107.3K
38BAXBaxter International Inc.history →Common0.63%$14M165.0K
39ABGAmerisourceBergen Corp.history →Common0.63%$14M174.3K
40EWEdwards Lifesciences Corp.history →Common0.63%$14M65.2K
41WELLWelltower Inc.history →Common0.60%$14M152.3K
42IDXXIDEXX Laboratories, Inc.history →Common0.59%$14M49.8K
43ALNYAlnylam Pharmaceuticals, Inc.history →Common0.58%$13M166.3K
44Bluebird Bio, Inc.Common0.56%$13M140.3K
45NVONovo Nordisk A/Shistory →Sponsored ADR0.54%$12M241.0K
46AZNNAstraZeneca PLChistory →Sponsored ADR0.54%$12M276.1K
47SG7Sage Therapeutics Inchistory →Common0.53%$12M86.8K
48HCAHCA Healthcare, Inc.history →Common0.52%$12M98.4K
49ONCBeiGene, Ltd.history →Sponsored ADR0.50%$12M94.3K
50Omega Healthcare Investors, Inc.Common0.50%$11M272.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2023$2.6B166Aug 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$2.6B177May 10, 202313F-HRchanges · EDGAR ↗
Q4 2022$2.6B172Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.4B169Nov 1, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.5B177Jul 29, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.8B175May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.1B171Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.1B172Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.1B189Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B196May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B200Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.7B204Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$2.6B222Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.2B217May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.6B214Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.3B192Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.5B197Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.5B194May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.3B203Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.